

1 VIRGINIA ACTS OF ASSEMBLY — CHAPTER

2 An Act to amend and reenact § 54.1-3303 of the Code of Virginia, relating to TPA-certified
3 optometrists; prescription of certain Schedule II controlled substances.

4 [H 498]
5 Approved

6 Be it enacted by the General Assembly of Virginia:

7 1. That § 54.1-3303 of the Code of Virginia is amended and reenacted as follows:

8 § 54.1-3303. Prescriptions to be issued and drugs to be dispensed for medical or therapeutic
9 purposes only.

10 A. A prescription for a controlled substance may be issued only by a practitioner of medicine,
11 osteopathy, podiatry, dentistry or veterinary medicine who is authorized to prescribe controlled
12 substances, or by a licensed nurse practitioner pursuant to § 54.1-2957.01, a licensed physician assistant
13 pursuant to § 54.1-2952.1, or a TPA-certified optometrist pursuant to Article 5 (§ 54.1-3222 et seq.) of
14 Chapter 32. The prescription shall be issued for a medicinal or therapeutic purpose and may be issued
15 only to persons or animals with whom the practitioner has a bona fide practitioner-patient relationship.

16 For purposes of this section, a bona fide practitioner-patient-pharmacist relationship is one in which a
17 practitioner prescribes, and a pharmacist dispenses, controlled substances in good faith to his patient for
18 a medicinal or therapeutic purpose within the course of his professional practice. In addition, a bona fide
19 practitioner-patient relationship means that the practitioner shall (i) ensure that a medical or drug history
20 is obtained; (ii) provide information to the patient about the benefits and risks of the drug being
21 prescribed; (iii) perform or have performed an appropriate examination of the patient, either physically
22 or by the use of instrumentation and diagnostic equipment through which images and medical records
23 may be transmitted electronically; except for medical emergencies, the examination of the patient shall
24 have been performed by the practitioner himself, within the group in which he practices, or by a
25 consulting practitioner prior to issuing a prescription; and (iv) initiate additional interventions and
26 follow-up care, if necessary, especially if a prescribed drug may have serious side effects.

27 For the purpose of prescribing a Schedule VI controlled substance to a patient via telemedicine
28 services as defined in § 38.2-3418.16, a prescriber may establish a bona fide practitioner-patient
29 relationship by an examination through face-to-face interactive, two-way, real-time communications
30 services or store-and-forward technologies when all of the following conditions are met: (a) the patient
31 has provided a medical history that is available for review by the prescriber; (b) the prescriber obtains
32 an updated medical history at the time of prescribing; (c) the prescriber makes a diagnosis at the time of
33 prescribing; (d) the prescriber conforms to the standard of care expected of in-person care as appropriate
34 to the patient's age and presenting condition, including when the standard of care requires the use of
35 diagnostic testing and performance of a physical examination, which may be carried out through the use
36 of peripheral devices appropriate to the patient's condition; (e) the prescriber is actively licensed in the
37 Commonwealth and authorized to prescribe; (f) if the patient is a member or enrollee of a health plan or
38 carrier, the prescriber has been credentialed by the health plan or carrier as a participating provider and
39 the diagnosing and prescribing meets the qualifications for reimbursement by the health plan or carrier
40 pursuant to § 38.2-3418.16; and (g) upon request, the prescriber provides patient records in a timely
41 manner in accordance with the provisions of § 32.1-127.1:03 and all other state and federal laws and
42 regulations. Nothing in this paragraph shall permit a prescriber to establish a bona fide
43 practitioner-patient relationship for the purpose of prescribing a Schedule VI controlled substance when
44 the standard of care dictates that an in-person physical examination is necessary for diagnosis. Nothing
45 in this paragraph shall apply to: (1) a prescriber providing on-call coverage per an agreement with
46 another prescriber or his prescriber's professional entity or employer; (2) a prescriber consulting with
47 another prescriber regarding a patient's care; or (3) orders of prescribers for hospital out-patients or
48 in-patients.

49 Any practitioner who prescribes any controlled substance with the knowledge that the controlled
50 substance will be used otherwise than medicinally or for therapeutic purposes shall be subject to the
51 criminal penalties provided in § 18.2-248 for violations of the provisions of law relating to the
52 distribution or possession of controlled substances.

53 B. In order to determine whether a prescription that appears questionable to the pharmacist results
54 from a bona fide practitioner-patient relationship, the pharmacist shall contact the prescribing practitioner
55 or his agent and verify the identity of the patient and name and quantity of the drug prescribed. The
56 person knowingly filling an invalid prescription shall be subject to the criminal penalties provided in

ENROLLED

HB498ER

57 § 18.2-248 for violations of the provisions of law relating to the sale, distribution or possession of
58 controlled substances.

59 No prescription shall be filled unless there is a bona fide practitioner-patient-pharmacist relationship.
60 A prescription not issued in the usual course of treatment or for authorized research is not a valid
61 prescription.

62 C. Notwithstanding any provision of law to the contrary and consistent with recommendations of the
63 Centers for Disease Control and Prevention or the Department of Health, a practitioner may prescribe
64 Schedule VI antibiotics and antiviral agents to other persons in close contact with a diagnosed patient
65 when (i) the practitioner meets all requirements of a bona fide practitioner-patient relationship, as
66 defined in subsection A, with the diagnosed patient; (ii) in the practitioner's professional judgment, the
67 practitioner deems there is urgency to begin treatment to prevent the transmission of a communicable
68 disease; (iii) the practitioner has met all requirements of a bona fide practitioner-patient relationship, as
69 defined in subsection A, for the close contact except for the physical examination required in clause (iii)
70 of subsection A; and (iv) when such emergency treatment is necessary to prevent imminent risk of
71 death, life-threatening illness, or serious disability.

72 D. A pharmacist may dispense a controlled substance pursuant to a prescription of an out-of-state
73 practitioner of medicine, osteopathy, podiatry, dentistry or veterinary medicine authorized to issue such
74 prescription if the prescription complies with the requirements of this chapter and the Drug Control Act
75 (§ 54.1-3400 et seq.).

76 E. A licensed nurse practitioner who is authorized to prescribe controlled substances pursuant to
77 § 54.1-2957.01 may issue prescriptions or provide manufacturers' professional samples for controlled
78 substances and devices as set forth in the Drug Control Act (§ 54.1-3400 et seq.) in good faith to his
79 patient for a medicinal or therapeutic purpose within the scope of his professional practice.

80 F. A licensed physician assistant who is authorized to prescribe controlled substances pursuant to
81 § 54.1-2952.1 may issue prescriptions or provide manufacturers' professional samples for controlled
82 substances and devices as set forth in the Drug Control Act (§ 54.1-3400 et seq.) in good faith to his
83 patient for a medicinal or therapeutic purpose within the scope of his professional practice.

84 G. A TPA-certified optometrist who is authorized to prescribe controlled substances pursuant to
85 Article 5 (§ 54.1-3222 et seq.) of Chapter 32 may issue prescriptions in good faith or provide
86 manufacturers' professional samples to his patients for medicinal or therapeutic purposes within the
87 scope of his professional practice for the drugs specified on the TPA-Formulary, established pursuant to
88 § 54.1-3223, which shall be limited to (i) *analgesics included on Schedule II controlled substances as*
89 *defined in § 54.1-3448 of the Drug Control Act (§ 54.1-3400 et seq.) consisting of hydrocodone in*
90 *combination with acetaminophen;* (ii) oral analgesics included in Schedules III through VI, as defined in
91 §§ 54.1-3450 and 54.1-3455 of the Drug Control Act (§ 54.1-3400 et seq.), which are appropriate to
92 relieve ocular pain; (iii); (iv) other oral Schedule VI controlled substances, as defined in § 54.1-3455 of
93 the Drug Control Act, appropriate to treat diseases and abnormal conditions of the human eye and its
94 adnexa; (v) topically applied Schedule VI drugs, as defined in § 54.1-3455 of the Drug Control
95 Act; and (vi) intramuscular administration of epinephrine for treatment of emergency cases of
96 anaphylactic shock.

97 H. The requirement for a bona fide practitioner-patient relationship shall be deemed to be satisfied by
98 a member or committee of a hospital's medical staff when approving a standing order or protocol for the
99 administration of influenza vaccinations and pneumococcal vaccinations in a hospital in compliance with
100 § 32.1-126.4.